Member Info for RayPointer

Excellent list Vanx2

If I may add a few more

15 a phase 1/2 trial of scib1 showing outstanding results
16 Scancell believe immunobody to be unique due to the dual presentation of the vaccine to APCs. This is what gives immunobody much of its potency
17 the grand challenge entry has a certain Ira Mellman on Lindy's team. He is a vice president of Genentech and a well respected scientist.
18 Lindy believes Moditope is powerful enough to not require help from CIs
19 Scancell had identified 37 different targets for Moditope at the last count. Only a handful of these are included in modi1 and 2. Only 7 of the targets have been tested so far but all 7 show the potential to attack cancer cells
20 both platforms have the potential to treat a wide range of cancers

ATB

Start with the Scancell website and search for the Feb 18 Hardman report.
There is also an RNs for this report.
Also the proactive website has interviews with Scancell
Good luck

Each trial is preceded by a number of development tasks and also satisfying the regulatory authority.
But let's summarise the current position

Modi1 is financed to start using money from the oo/placing
Let's also assume the modi2 development is also financed by this (Scancell did say this)
Modi3 is financed if we win the grand challenge.

A deal with Biontech will help to finance whatever Scancell see fit. This is assuming there is an upfront payment.
This is an unknown at present but, as Inan has already pointed out, 1 deal could lead to further deals as Moditope becomes successful.

To me, the key has always been the Modi1 trial. The first sign of success will certainly convert potential energy to kinetic energy. And that means that, if an extra placing is required, the share dilution will be much less.

I would also not discount more financial help from Cruk.

As for the speed of getting multiple modi trials underway well, it all depends on Scancell's resources and their determination to not share the IP. The 3 card trick of winning the GC, a deal with Biontech and initial signs of Mod1 success will, IMHO, see us home and dry.

Not to forget that we also have 2 immunobody trials.

Going back to Scancell's limited resources, then I would not expect every deadline to be met. Some events will be outside Scancell's control as we are seeing now with the scib1 combo trial.
So, in summary, I feel Scancell have enough on their plate with the current timetable.

3 trials planned, any one of which could be a game changer.

The grand challenge results looming.

The ongoing collaboration with Biontech.

so, tick tock times 5.

Then the science does not stand still with

Modi2 being developed
The glycan platform
The exciting new moditope target

Another 3 tick tocks albeit fainter in volume.

Yes, the science is outstripping the trials but think of it as potential energy that could explode at anytime as events unfold. The potential energy becomes kinetic energy!

Yes, but there must be a big stock overhang after the Newlands sale. Shaping up to a nice buying opportunity.

Nigel Blackburn! That doesn't bode well LOL

Is half a Nobel prize a "No prize" or a "Nob prize"? LOL

Oh and thanks to Rats too who beat me to it in pointing out the RA connection

Thanks to DA and C7 for their posts.

It appears that homocitrulline appears in antibodies for RA sufferers.
So again we have the RA connection. Lindy having found the citrullinated moditope targets is continuing looking for antibody differences in RA patients as opposed to people without RA.
We will probably hear more is due course. It may be that the moditope patent may require update to include this target but, on the other hand, it may already be covered in the definition of citrullinated targets.

Great post Rats.
A few more musings about the grand challenge.

The blueprint may possibly be something like this

1) try the appropriate modix vaccine on the patient. This is because it would be the cheapest way of killing the cancer
2) in the event of failure (e.g. an immune desert as Ira Mellman puts it) use diagnostics (Roche?) to find the best citrullinated targets
3) isolate and clone the Tcell(S) using Biontech TCR technology and kill the cancer this way (cut out the middle man I.e. the APC that moditope uses)

No disrespect to the other members of the team. They are all first class scientists in their particular areas of expertise and I am sure they will all contribute. However, it seems to me, that Scancell, Biontech and Roche are the key players.

Of course we have to win the grand challenge first.
Let's assume we win the GC. Just imagine then how much interest there will be on the modi1 trial from big pharmas.

IMHO of course

Deadly
I posted that the latest possible AGM date is 31st Oct since by law it must be within 6 months of the end accounting date (30th April). Not sure how much notice must be given but hope this helps.

As I understand it, public companies must hold an AGM within 6 months of the accounting end date: So 31 Oct is the latest AGM date.

Max, what I meant was that they should be able to clarify the policy and constraints for divulging information about the Scib2 trial.
So, for instance, they could say that they are awaiting final agreement with Cruk before issuing an RNS.

Alternatively, they could say that information on the trial will appear on the Cruk website. In this case they may issue an RNs just to say refer to CRuk website whenever something of import happens concerning the trial. IMO it is best to have all up-to-date information on the trial in one place.

I suppose Scancell are erring on the side of caution until the 3 parties ( Scancell, Cruk, the regulator) all agree on the trial makeup. The AGM should clarify.

Yes, cruk and Scancell should have already decided how news of the Scib2 trial should be issued.

So, if this figure of 75 patients is true, does this raise the possibility of Scib2 gaining approval if the results are outstanding?
Could this also be the thinking behind increasing the scope of the scib1 trial to include the UK.

I would be interested to hear other posters' views on this. Are there precedents of drugs gaining approval following trials with around this number of patients?

Might be a good time to buy if tomorrow's news, as well as reporting the annual accounts, also gives us positive project updates. On the subject of the grand challenge result announcement going back to January, it may well be because one or more submissions are not ready. In fact Lindy may well have asked for more time since she is so busy.

No, just confirmation that everything is going roughly to schedule or not as the case may be.
Also it is obvious now that around 12p or just under is a support level. The level attracted buyers of which I was one.

The only reason I can think of is that the RNs next week may contain a status report on all the various projects.

Thanks inan

Hi Inan Amplivant - how does it actually work? I'm guessing that it increases the avidity of the T cells.